Last reviewed · How we verify

NCT07203131: NI-AKI

Evaluation of the Impact of an Alteration of NAD+ Metabolism on the Renal Prognosis of Patients Admitted to Intensive Care (NI-AKI)

Recruiting now NA Last updated 2 October 2025
What this trial tests

NA trial testing Urine sample in Acute Renal Insufficiency in 150 participants. Currently enrolling.

Timeline
17 March 2025
Primary endpoint
5 November 2025
5 December 2025

Quick facts

Lead sponsorRamsay Générale de Santé
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposescreening
Enrollment150
Start date17 March 2025
Primary completion5 November 2025
Estimated completion5 December 2025
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Ramsay Générale de Santé — full company profile →

Who can join

18 and older, any sex, with Acute Renal Insufficiency or NAD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Among all patients admitted to intensive care, it is estimated that more than half of them are exposed during their stay to acute renal failure (ARF). Impacting the vital prognosis to short term, the occurrence of renal failure is not without consequences in intensive care survivors, presenting an increased risk of death mainly mediated by an excess risk with regard to chronic kidney disease and/or certain cardiovascular pathologies. Malnutrition, particularly vitamin deficiency, has already been reported as a risk factor for AKI. Studies on two models (animal and human) have recently highlighted the importance of NAD+ production failure in the onset of renal failure. NAD+ synthesis can be done from tryptophan or via a salvage pathway from vitamin PP. In a phase 2 study in patients undergoing cardiac surgery, vitamin B3 supplementation was accompanied by a reduction in the occurrence of AKI and a limitation of the duration / intensity of renal dysfunction. This innovative research aims to identify an alteration in the metabolic pathway of NAD+ production as a risk factor for AKI in intensive care patients. This would be the first study to address this issue in this specific population. The main objective of this research is to describe the association between the urinary Quinolinate/Tryptophan ratio on admission and the occurrence of acute renal failure in patients admitted to intensive care unit.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Urine sample

Trials testing the same drug.

Other recruiting trials for Acute Renal Insufficiency

Currently open trials in the same condition.

Other Ramsay Générale de Santé trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07203131.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing